Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence, AUC, Cmax, Pharmacokinetics
Conditions
Bioequivalence, AUC, Cmax, Pharmacokinetics
Trial Timeline
Oct 11, 2016 → Nov 19, 2016
NCT ID
NCT03121820About Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mg
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mg is a phase 1 stage product being developed by GEROPHARM for Bioequivalence, AUC, Cmax, Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT03121820. Target conditions include Bioequivalence, AUC, Cmax, Pharmacokinetics.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03121820 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence, AUC, Cmax, Pharmacokinetics